Related references
Note: Only part of the references are listed.Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2021)
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)
Thomas Cluzeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D. DiNardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
How I treat acute myeloid leukemia in the era of new drugs
Courtney D. DiNardo et al.
BLOOD (2020)
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes
Fevzi F. Yalniz et al.
CANCER (2020)
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols
Marta Sitges et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Tobias Herold et al.
LEUKEMIA (2020)
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years
Ann-Kathrin Eisfeld et al.
LEUKEMIA (2020)
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease
Alex Bataller et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis
Ayaka Yamaoka et al.
BLOOD ADVANCES (2020)
Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation
Alec Britt et al.
LEUKEMIA RESEARCH (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
Krzysztof Mrozek et al.
LEUKEMIA (2019)
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes
Prajwal C. Boddu et al.
CANCER (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation
Kazimierz Halaburda et al.
BONE MARROW TRANSPLANTATION (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study
Yasuhiko Harada et al.
LEUKEMIA RESEARCH (2018)
Interpretation of clinical endpoints in trials of acute myeloid leukemia
Bruno C. Medeiros
LEUKEMIA RESEARCH (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
A-K Eisfeld et al.
LEUKEMIA (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis
Saori Katayama et al.
BLOOD (2017)
Genomic Classification in Acute Myeloid Leukemia
Francois Lemonnier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
Stefan Groeschel et al.
CELL (2014)
Survival analysis in hematologic malignancies: recommendations for clinicians
Julio Delgado et al.
HAEMATOLOGICA (2014)
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
Marta Pratcorona et al.
BLOOD (2013)
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
Krzysztof Mrozek et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System
Christoph Roellig et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia
Sanne Lugthart et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia
Tobias Benthaus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
P. Gorello et al.
LEUKEMIA (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
